Please select the option that best describes you:

How would you manage a male patient who has a germline BRCA2 mutation with node-positive, HR-positive invasive ductal carcinoma who is unable/unwilling to receive tamoxifen or AI + goserelin?  

Is there a role for raloxifene, PARP inhibition, or CDK4/6 inhibition? If so, how would you sequence?
Patient has RS 22, G2, < 3 LN positive after mastectomy and ALND; declined chemotherapy.
Also in year 3 of remission from pancreatic cancer s/p gem/nab-paclitaxel